Penn Pharma
The API isolator with rapid transfer ports and flexibility to use disposable Hicoflex technology.
Penn Pharma has exceeded expectations and is on track to deliver its ambitious growth expectations after securing multiple contracts with companies from across the globe less than two months after officially opening the doors of its new contained manufacturing facility.
The company, based in Tredegar, South Wales, UK, has recently signed contracts with customers, including those from Europe, America and Japan, after opening the new facility, which contains cutting edge technology for the manufacture of products containing highly potent compounds.
Penn announced its plans to build the new facility in 2012 and the first batch of coated tablets was produced in May of this year.
The facility has been purpose-built to meet the growing market need for truly contained manufacturing processes. Successfully securing multiple global contracts in such a short space of time has verified Penn’s vision and investment strategy that led to the design and build of this new state-of-the-art facility.
With each contract signed, Penn continues to demonstrate its leadership in this market and is fast becoming the go to company for solid dosage form contained manufacturing.
Richard Yarwood, Penn Pharma’s Chief Executive Officer, said: “Our vision is to become the preferred partner for the supply of oral doses containing potent molecules for both investigational and commercial use and this facility will help us to achieve this.
“The fact that we have secured several contracts with international customers so quickly after opening demonstrates that we have provided a superior solution to meet customer needs. At Penn, we offer seamless development and manufacturing services using highly contained equipment trains that fully contain active ingredients and minimise the need for personal protective equipment (PPE).”
Penn Pharma delivers integrated drug development, clinical trial supply and manufacturing services to the international healthcare industry.
Penn Pharmaceutical Services Ltd, +44 1495 711 222, www.pennpharm.co.uk.